Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Clinical trial NCT07349693 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07349693
- Sponsor
- Everfront Biotech Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-11-01
- Primary completion
- 2028-12-01
- Enrollment
- 175
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.